Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 15/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676998 | 1.00 | SLC6A1 (1.00) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL10964540 | 0.99 | ALDH1A1 (1.00) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL9524452 | 0.93 | SLC6A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL9524447 | 0.93 | SLC6A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL9528572 | 0.92 | ALDH1A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL10965807 | 0.92 | ALDH1A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL9528575 | 0.92 | ALDH1A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL10968322 | 0.91 | ALDH1A1 (0.86) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL8820149 | 0.91 | SLC6A1 (0.83) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL8820154 | 0.91 | SLC6A1 (0.83) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912091-B1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-12-19 | — | — | EP | claimed |
| EP-0912091-A4 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1142584-A1 | COMPOSITIONS FOR TREATING FREQUENT URINATION AND URINARY INCONTINENCE | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | claimed |
| US-6121290-A | TREATING COUGH BY ADMINISTERING A COMPOUND THAT INHIBITS GABA (GAMMA-AMINO-BUTYRIC ACID) UPTAKE, SUCH AS GUVACINE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-19 | — | — | US | claimed |
| JP-2000511538-A | — | — | 2000-09-05 | — | — | JP | claimed |
| EP-0912091-A1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1997043902-A1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-27 | — | — | WO | claimed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-0912091-A4 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1142584-A1 | COMPOSITIONS FOR TREATING FREQUENT URINATION AND URINARY INCONTINENCE | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6121290-A | TREATING COUGH BY ADMINISTERING A COMPOUND THAT INHIBITS GABA (GAMMA-AMINO-BUTYRIC ACID) UPTAKE, SUCH AS GUVACINE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0912091-A1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997043902-A1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A1 2250/4885ALDH1A1 2164/4885LMNA 3625/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | SLC6A1 2093/4885ALDH1A1 1565/4885LMNA 2155/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | SLC6A1 2250/4885ALDH1A1 2164/4885LMNA 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.